The trial for a bird flu vaccine targeting the H5N1 strain has commenced in the UK. This strain has caused significant infections in bird populations globally but has not yet spread among humans. The first volunteers have been immunized with the vaccine, which aims to protect against a potential pandemic.
Vaccine Development and Trial Details
The vaccine utilizes mRNA technology, similar to that used in current Covid-19 vaccines. This technology allows for rapid production and scalability in the event of a pandemic. The trial is particularly focused on recruiting individuals who work in the poultry industry and those over the age of 65, as these groups are considered most at risk.
Clare Howard, a volunteer from Hampshire with experience in keeping chickens, was among the first to receive the vaccine at a clinic in Southampton. The large-scale trial aims to involve 4,000 volunteers, with three-quarters being recruited from 26 sites across England and Scotland, and the remainder from the United States.
Research Goals and Safety Measures
The study will assess the vaccine’s safety and its ability to generate a robust immune response. If successful, it could be licensed for use if necessary. Dr. Rebecca Clark, the trial’s national co-ordinating investigator, emphasized the importance of preparing for potential human-to-human transmission of the virus, which, while currently low, remains a possibility.
Since 2024, there have been 116 confirmed human cases of H5N1 globally, almost all linked to close contact with infected animals. The trial is seen as a proactive measure to enhance pandemic preparedness.
Manufacturing and Future Implications
If the vaccine is deemed necessary, it will be produced at Moderna’s facility in Harwell, Oxfordshire, which currently manufactures Covid vaccines for the UK. This facility has the capacity to produce 100 million doses annually, with the potential to increase output to 250 million doses during a pandemic.
Traditional flu vaccine production methods involve growing the virus in eggs, which can be problematic with virulent strains like H5N1. The mRNA approach offers a more adaptable solution, as demonstrated during the Covid pandemic when these vaccines were shown to be effective and could be modified quickly as strains evolved.
Flu pandemics are considered inevitable, although the timing remains uncertain. The last significant pandemic occurred in 2009 with the swine flu, which was relatively mild compared to historical outbreaks like the Spanish flu, which resulted in approximately 50 million deaths worldwide.
Funding for the trial has been provided by the Coalition for Epidemic Preparedness Innovations (CEPI), which allocated £40 million to support the initiative. This funding aims to ensure equitable access to the vaccine for low and middle-income countries in the event of a future pandemic, addressing concerns about “vaccine nationalism” that emerged during the Covid-19 crisis.
Source: Original report